2-methylene-vitamin D analogs and their uses

• US 8,410,080 B1
• Filed: 10/11/2012
• Issued: 04/02/2013
• Est. Priority Date: 10/21/2011
• Status: Active Grant

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: DeLuca, Hector F., Plum, Lori A., Sicinski, Rafal R., Sibilska, Izabela
• Primary Examiner(s): QAZI, SABIHA NAIM
• Application Number:
  US13/649,240
• Publication Number:
  US 20130102574A1
• Time in Patent Office: 173 Days
• Field of Search: 514/167, 552/653
• US Class Current: 514/167
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07C 2601/14 The ring being saturated
• CPC Class Codes: C07C 2602/24 the ring system containing nine carbon atoms, e.g. perhydroindane
• CPC Class Codes: C07C 401/00 Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
• CPC Class Codes: C07F 7/1804 Compounds having Si-O-C linkages Si-O-acyl linkages C07F7/1896

Abstract

This invention discloses 2-methylene-vitamin D analogs, and specifically (20S)-1α,25 -dihydroxy-2-methylene-vitamin D₃ as well as (5E)-(20S)-1α,25-dihydroxy-2 -methylene-vitamin D₃ and (20R)-1α,25-dihydroxy-2-methylene-vitamin D₃, as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also have relatively high calcemic activities evidencing use in the treatment of bone diseases.

Claims

1. A compound having the formula:

2. The compound of claim 1 wherein X₁ and X₂ are both hydrogen.

3. The compound of claim 1 wherein R is selected from:

4. The compound of claim 3 wherein X₁ and X₂ are both hydrogen.

5. A pharmaceutical composition containing an effective amount of at least one compound as claimed in claim 1 together with a pharmaceutically acceptable excipient.

6. The pharmaceutical composition of claim 5 wherein said effective amount comprises from about 0.01 μ

g to about 1000 μ

g per gram of composition.

7. The pharmaceutical composition of claim 5 wherein said effective amount comprises from about 0.1 μ

g to about 500 μ

g per gram of composition.

8. A compound having the formula:

9. A pharmaceutical composition containing an effective amount of (20S)-1α

,25-dihydroxy-2-methylene-vitamin D₃ together with a pharmaceutically acceptable excipient.

10. The pharmaceutical composition of claim 9 wherein said effective amount comprises from about 0.01 μ

g to about 1000 g per gram of composition.

11. The pharmaceutical composition of claim 9 wherein said effective amount comprise from about 0.1 μ

g to about 500 μ

g per gram of composition.

12. A compound having the formula:

13. A pharmaceutical composition containing an effective amount of (5E)-(20S)-1α

,25-dihydroxy-2-methylene-vitamin D₃ together with a pharmaceutically acceptable excipient.

14. The pharmaceutical composition of claim 13 wherein said effective amount comprises from about 0.01 μ

g to about 1000 μ

g per gram of composition.

15. The pharmaceutical composition of claim 13 wherein said effective amount comprises from about 0.1 μ

g to about 500 μ

g per gram of composition.

16. A compound having the formula:

17. A pharmaceutical composition containing an effective amount of (20R)-1α

,25-dihydroxy-2-methylene-vitamin D₃ together with a pharmaceutically acceptable excipient.

18. The pharmaceutical composition of claim 17 wherein said effective amount comprises from about 0.01 μ

g to about 1000 μ

g per gram of composition.

19. The pharmaceutical composition of claim 17 wherein said effective amount comprises from about 0.01 μ

g to about 500 μ

g per gram of composition.

20. A method of treating a disease selected from the group consisting of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer comprising administering to a subject with said disease an effective amount of a 2-methylene-vitamin D analog having the formula:

21. The method of claim 20 wherein the vitamin D analog is administered orally.

22. The method of claim 20 wherein the vitamin D analog is administered parenterally.

23. The method of claim 20 wherein the vitamin D analog is administered transdermally.

24. The method of claim 20 wherein the vitamin D analog is administered rectally.

25. The method of claim 20 wherein the vitamin D analog is administered nasally.

26. The method of claim 20 wherein the vitamin D analog is administered sublingually.

27. The method of claim 20 wherein the vitamin D analog is administered in a dosage of from about 0.01 μ

g/day to about 1000 μ

g/day.

28. The method of claim 20 wherein the vitamin D analog has the formula:

29. The method of claim 20 wherein the vitamin D analog has the formula:

30. The method of claim 20 wherein the vitamin D analog has the formula:

31. A method of treating metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of a compound having the formula:

32. The method of claim 31 wherein the compound is administered orally.

33. The method of claim 31 wherein the compound is administered parenterally.

34. The method of claim 31 wherein the compound is administered transdermally.

35. The method of claim 31 wherein the compound is administered rectally.

36. The method of claim 31 wherein the compound is administered nasally.

37. The method of claim 31 wherein the compound is administered sublingually.

38. The method of claim 31 wherein the compound is administered in a dosage of from about 0.01 μ

g/day to about 1000 μ

g/day.

39. The method of claim 31 where the disease is senile osteoporosis.

40. The method of claim 31 where the disease is postmenopausal osteoporosis.

41. The method of claim 31 where the disease is steroid-induced osteoporosis.

42. The method of claim 31 where the disease is low bone turnover osteoporosis.

43. The method of claim 31 where the disease is osteomalacia.

44. The method of claim 31 where the disease is renal osteodystrophy.

45. The method of claim 31 wherein the compound has the formula:

46. The method of claim 31 wherein the compound has the formula:

47. The method of claim 31 wherein the compound has the formula: